Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

  • Darja Urlep Department of Gastroenterology, Hepatology and Nutrition, University Children’s Hospital Ljubljana, University Medical Centre Ljubljana, Slovenia
  • Vojislav N. Perisic University Children’s Hospital, Belgrade, Serbia
  • Rok Orel department of gastroenterology, Hepatology and nutrition, University Children’s Hospital Ljubljana, University Medical Centre Ljubljana, Bohoričeva 20, 1000 Ljubljana, Slovenia
Keywords: pediatric inflammatory bowel disease, treatment, anti-TNF agents, infliximab, adalimumab

Abstract

Over the last 10 years, biologic treatment with the antitumor necrosis factor (anti-TNF) antibodies has dramatically changed the therapeutic approach in pediatric patients with inflammatory bowel disease (IBD). Currently, infliximab and adalimumab are the only anti-TNF drugs that have been approved for use in refractory pediatric Crohn’s disease (CD) and infliximab the only anti-TNF agent for use in refractory pediatric ulcerative colitis (UC). According to the current treatment recommendations, anti-TNF therapy is indicated for moderate and severe pediatric IBD when remission is not achieved using conventional treatment or conventional therapy is not tolerated by the patients.

Despite the demonstrated efficacy of anti-TNF drugs in pediatric IBD patients, the potential development of serious adverse events, such as severe immune reactions, infections, and malignancies, limit the possibility of a wider use of anti-TNF drugs. Moreover, a substantial percentage of patients gradually develop non-responsiveness to these therapeutics, due to generation of antibodies against anti-TNF antibodies. Therefore, treatment of pediatric IBD patients with biologics should be undertaken in specialized tertiary medical centers, which are specially qualified for this purpose.

Downloads

Download data is not yet available.
Published
2013-10-18
How to Cite
1.
Urlep D, N. Perisic V, Orel R. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. TEST ZdravVestn [Internet]. 18Oct.2013 [cited 16May2024];82. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/692
Issue
Vol 82 (2013): Supplement I
Section
Review


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.